-transparent.png){kind=logo}
The aim of this study was to compare the clinical and bacteriologic efficacy of meropenem with imipenem/cilastatin in the treatment of obstetric and gynecologic infections. This was a controlled, multicenter, randomized study with two parallel groups and a follow-up period of up to 4 weeks. A total of 105 hospital in-patients requiring antibacterial parenteral therapy were enrolled, 52 in the meropenem group and 53 in the imipenem/cilastatin group. Both drugs were administered at 0.5 g every 8 hours, by slow intravenous infusion over 20-30 minutes; for meropenem the administration by intravenous bolus injection (over approximately 5 minutes) was allowed. The mean duration of therapy was 5 days for both treatments. At the end of treatment, all 46 evaluable patients in the meropenem treatment group had a satisfactory clinical response, while in the imipenem/cilastatin group 5/49 patients were clinical failures. The difference between the treatment groups in clinical response was statistically significant (100% vs 89.8%; p=.026). A similar result was seen in the intention-to-treat analysis (98% vs 84.6%; p=0.017). Both treatments were well tolerated, but fewer meropenem patients experienced treatment-related adverse events in comparison with imipenem/cilastatin (11.5% vs 15.1%).
P Maggioni, and
F Di Stefano, and
V Facchini, and
S Irato, and
S Mancuso, and
M Colombo, and
M Massobrio, and
G B Melis, and
P Crosignani
June 1985,
The American journal of medicine,
P Maggioni, and
F Di Stefano, and
V Facchini, and
S Irato, and
S Mancuso, and
M Colombo, and
M Massobrio, and
G B Melis, and
P Crosignani
May 1986,
The Japanese journal of antibiotics,
P Maggioni, and
F Di Stefano, and
V Facchini, and
S Irato, and
S Mancuso, and
M Colombo, and
M Massobrio, and
G B Melis, and
P Crosignani
January 1985,
Reviews of infectious diseases,
P Maggioni, and
F Di Stefano, and
V Facchini, and
S Irato, and
S Mancuso, and
M Colombo, and
M Massobrio, and
G B Melis, and
P Crosignani
January 1995,
The Journal of antimicrobial chemotherapy,
P Maggioni, and
F Di Stefano, and
V Facchini, and
S Irato, and
S Mancuso, and
M Colombo, and
M Massobrio, and
G B Melis, and
P Crosignani
March 1986,
Surgery, gynecology & obstetrics,
P Maggioni, and
F Di Stefano, and
V Facchini, and
S Irato, and
S Mancuso, and
M Colombo, and
M Massobrio, and
G B Melis, and
P Crosignani
June 1993,
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
P Maggioni, and
F Di Stefano, and
V Facchini, and
S Irato, and
S Mancuso, and
M Colombo, and
M Massobrio, and
G B Melis, and
P Crosignani
May 2005,
Current medical research and opinion,
P Maggioni, and
F Di Stefano, and
V Facchini, and
S Irato, and
S Mancuso, and
M Colombo, and
M Massobrio, and
G B Melis, and
P Crosignani
September 1997,
Enfermedades infecciosas y microbiologia clinica,
P Maggioni, and
F Di Stefano, and
V Facchini, and
S Irato, and
S Mancuso, and
M Colombo, and
M Massobrio, and
G B Melis, and
P Crosignani
July 1995,
The Journal of antimicrobial chemotherapy,
P Maggioni, and
F Di Stefano, and
V Facchini, and
S Irato, and
S Mancuso, and
M Colombo, and
M Massobrio, and
G B Melis, and
P Crosignani
March 1998,
Connecticut medicine,
